Low molecular weight heparin decreases the permeability of glomerular endothelial cells when exposed to pre-eclampsia serum in vitro.
Low molecular weight heparin (LMWH) has been used to treat certain kidney diseases such as pre-eclampsia, in which extensive levels of proteinuria are associated with dysfunction of glomerular endothelium. In our study, we investigated whether LMWH could affect the permeability of and ET-1 expression in human glomerular endothelial cells (GEnC) incubated with pre-eclampsia serum. Serum from pre-eclampsia patients was collected and incubated with GEnC in the absence or presence of LMWH. We assessed the permeability of glomerular endothelial monolayer by measuring the amount of bovine serum albumin (BSA) that crosses into the lower chamber of a trans-well device. In addition, we measured ET-1 mRNA expression levels in and proliferation and apoptotic rates of GEnC exposed to pre-eclampsia serum with or without LMWH. The permeability of ET-1 mRNA expression in GEnC increased upon incubation with pre-eclampsia serum, but decreased significantly when LMWH was added. The presence of LMWH did not alter the proliferation and apoptosis of GEnC incubated with pre-eclampsia serum. Low molecular weight heparin maintains the integrity of the kidney probably by strengthening the defence of glomerular endothelium.